Previous studies have demonstrated that electronic patient-reported outcomes (ePROs) are helpful in capturing real-time radiation and chemo toxicities. The phase 3 PRO-TECT trial enrolled nearly 1200 patients receiving treatment for metastatic cancer and randomized them to ePRO versus usual care with an ambitious primary endpoint of overall survival. While we’re still waiting on that reporting, here we have the pre-planned secondary analysis on quality-of-life outcomes. As anticipated, patients completing ePROs had significant advantages in all three measures of physical function, symptom control, and health-related quality-of-life.
- Basch, JAMA 2022